TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:TSRO
- CUSIP: 88156910
- Web: www.tesarobio.com
Capitalization:- Market Cap: $5.90844 billion
- Outstanding Shares: 54,180,000
Average Prices:- 50 Day Moving Avg: $125.98
- 200 Day Moving Avg: $147.86
- 52 Week Range: $83.26 - $192.94
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -22.82
- P/E Growth: -0.51
Sales & Book Value:- Annual Revenue: $41.25 million
- Price / Sales: 149.55
- Book Value: $7.38 per share
- Price / Book: 15.43
Profitability:- EBIDTA: ($485,860,000.00)
- Net Margins: -1,301.19%
- Return on Equity: -104.00%
- Return on Assets: -71.79%
Debt:- Debt-to-Equity Ratio: 0.34%
- Current Ratio: 5.69%
- Quick Ratio: 5.41%
Misc:- Average Volume: 1.27 million shs.
- Beta: 1.59
- Short Ratio: 7.96
Frequently Asked Questions for TESARO (NASDAQ:TSRO)
What is TESARO's stock symbol?
TESARO trades on the NASDAQ under the ticker symbol "TSRO."
How were TESARO's earnings last quarter?
TESARO, Inc. (NASDAQ:TSRO) announced its earnings results on Tuesday, August, 8th. The company reported ($2.82) earnings per share for the quarter, missing analysts' consensus estimates of ($2.52) by $0.30. The firm had revenue of $29.50 million for the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. TESARO's quarterly revenue was down 17.6% on a year-over-year basis. During the same period in the prior year, the business earned ($1.28) EPS. View TESARO's Earnings History.
When will TESARO make its next earnings announcement?
Where is TESARO's stock going? Where will TESARO's stock price be in 2017?
21 brokers have issued 12 month price objectives for TESARO's shares. Their predictions range from $121.00 to $236.00. On average, they anticipate TESARO's stock price to reach $173.24 in the next year. View Analyst Ratings for TESARO.
What are analysts saying about TESARO stock?
Here are some recent quotes from research analysts about TESARO stock:
- 1. FBR & Co analysts commented, "We received our first data snapshot from the RX-3117 Phase 2a study in advanced muscle invasive bladder cancer at ASCO this weekend with data coming from 10 patients in stage 1 of the study. The study achieved the predefined efficacy criteria (two of ten patients achieving a PFS of at least four months or a partial or complete tumor response), where 22% of patients have experienced PFS for a minimum of six months. One of the two aforementioned patients is still on study, achieving 175 days of stable disease. While only stage 1 of this study, we believe it is important to point out that patients who have reached this stage of disease are usually limited to palliative or best supportive care." (6/5/2017)
- 2. Cann analysts commented, "On Saturday, June 3, 2017, Tesaro provided a corporate update that described initial data from the TOPACIO trial of niraparib (Zejula) plus Keytruda (pembrolizumab) and results of a phase I trial of TSR-042, and provided an update on the commercial launch of Zejula and its commercial businesses in the US and Europe. The launch is exceeding our expectations, and management reiterated plans to advance Zejula into the front-line ovarian cancer setting and to expand into other tumor types, including non-small cell lung cancer. We are adjusting our Zejula outlook based on the current status of the launch." (6/5/2017)
- 3. Cowen and Company analysts commented, "TSRO reported 1Q financials, provided a pipeline update and commented on Zejula’s." (5/11/2017)
- 4. According to Zacks Investment Research, "Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company's product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. " (3/31/2017)
- 5. Wedbush analysts commented, "With first-mover advantage in the maintenance setting, a lack of requirement for a diagnostic, as well clinical data that is at least as good as Lynparza in gBRCA patients, we continue to believe that TSRO remains an attractive acquisition candidate." (3/28/2017)
Who are some of TESARO's key competitors?
Some companies that are related to TESARO include Exelixis (EXEL), Kite Pharma (KITE), Bioverativ (BIVV), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), Ultragenyx Pharmaceutical (RARE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Axovant Sciences (AXON) and Prothena Corporation PLC (PRTA).
Who are TESARO's key executives?
TESARO's management team includes the folowing people:
- David M. Mott, Independent Chairman of the Board
- Mary Lynne Hedley Ph.D., President, Chief Operating Officer, Director
- Leon O. Moulder Jr., Chief Executive Officer, Director
- Timothy R. Pearson, Chief Financial Officer, Executive Vice President
- Jeffrey H. Hanke Ph.D., Executive Vice President - Research and Development, Chief Scientific Officer
- Joseph L. Farmer, Senior Vice President, General Counsel, Secretary
- Grant C. Bogle, Senior Vice President, Chief Commercial Officer
- Martin H. Huber M.D., Senior Vice President and Chief Medical Officer
- Lawrence M. Alleva, Independent Director
- James O. Armitage M.D., Independent Director
Who owns TESARO stock?
TESARO's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (19.08%), FMR LLC (14.29%), BlackRock Inc. (6.69%), Vanguard Group Inc. (5.53%), InterWest Venture Management Co (3.75%) and Franklin Resources Inc. (3.48%). Company insiders that own TESARO stock include Arnold L Oronsky, Edward C English, Enterprise Associates 13 L New, Grant C Bogle, James O Armitage, Jeffrey H Hanke, Martin H Jr Huber and Mary Lynne Hedley. View Institutional Ownership Trends for TESARO.
Who sold TESARO stock? Who is selling TESARO stock?
TESARO's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., FMR LLC, Northern Trust Corp, Federated Investors Inc. PA, Neuberger Berman Group LLC, Schwab Charles Investment Management Inc., Van ECK Associates Corp and TD Asset Management Inc.. Company insiders that have sold TESARO stock in the last year include Edward C English, Grant C Bogle, Jeffrey H Hanke, Martin H Jr Huber and Mary Lynne Hedley. View Insider Buying and Selling for TESARO.
Who bought TESARO stock? Who is buying TESARO stock?
TESARO's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, PointState Capital LP, Pioneer Investment Management Inc., BlackRock Inc., State Street Corp, Tobam, Fiera Capital Corp and Pictet Asset Management Ltd.. Company insiders that have bought TESARO stock in the last two years include Arnold L Oronsky, Enterprise Associates 13 L New and James O Armitage. View Insider Buying and Selling for TESARO.
How do I buy TESARO stock?
Shares of TESARO can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TESARO's stock price today?
One share of TESARO stock can currently be purchased for approximately $113.86.
MarketBeat Community Rating for TESARO (NASDAQ TSRO)MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for TESARO (NASDAQ:TSRO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 8 Hold Ratings, 13 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.62) |
| Consensus Price Target: | $173.24 (52.15% upside) |
Analysts' Ratings History for TESARO (NASDAQ:TSRO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/17/2017 | Jefferies Group LLC | Set Price Target | Hold | $124.00 | High |  |
| 8/18/2017 | Credit Suisse Group | Set Price Target | Buy | $198.00 -> $190.00 | High | |
| 8/16/2017 | Evercore ISI | Initiated Coverage | In -> In-Line | $121.00 | High | |
| 8/10/2017 | Robert W. Baird | Reiterated Rating | Neutral | $155.00 -> $140.00 | High | |
| 8/10/2017 | Morgan Stanley | Reiterated Rating | Overweight | $183.00 | High | |
| 7/14/2017 | Janney Montgomery Scott | Reiterated Rating | Neutral | | Low | |
| 7/7/2017 | Gabelli | Initiated Coverage | Buy | $175.00 | High | |
| 6/20/2017 | Raymond James Financial, Inc. | Reiterated Rating | Market Perform | | Medium | |
| 6/20/2017 | Leerink Swann | Lower Price Target | Market Perform | $164.00 -> $143.00 | High | |
| 6/20/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $236.00 | High | |
| 6/20/2017 | Bank of America Corporation | Reiterated Rating | Buy | $154.00 | High | |
| 6/19/2017 | Cowen and Company | Lower Price Target | Market Perform | $145.00 -> $124.00 | High | |
| 6/13/2017 | Wedbush | Reiterated Rating | Outperform | $160.00 -> $168.00 | High | |
| 6/5/2017 | FBR & Co | Lower Price Target | Mkt Perform -> Mkt Perform | $200.00 -> $195.00 | High | |
| 6/5/2017 | Cann | Reiterated Rating | Buy | $199.00 | High | |
| 6/4/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $183.00 -> $199.00 | High | |
| 4/22/2017 | Citigroup Inc. | Reiterated Rating | Buy | $232.00 -> $216.00 | Low | |
| 4/12/2017 | Piper Jaffray Companies | Initiated Coverage | Overweight -> Overweight | $180.00 | Low | |
| 3/24/2017 | Argus | Initiated Coverage | Buy | $210.00 | High | |
| 2/17/2017 | Royal Bank Of Canada | Boost Price Target | Outperform | $142.00 -> $202.00 | N/A | |
| 2/9/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy -> Average | $190.00 | N/A | |
| 11/7/2016 | Lake Street Capital | Reiterated Rating | Buy | $114.00 -> $150.00 | N/A | |
| 8/5/2016 | Mizuho | Lower Price Target | Buy | $100.00 -> $94.00 | N/A | |
(Data available from 8/20/2015 forward)
Earnings History for TESARO (NASDAQ:TSRO)Earnings History by Quarter for TESARO (NASDAQ TSRO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($1.16) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($2.52) | ($2.82) | $18.61 million | $29.50 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($2.26) | ($2.55) | $3.84 million | $3.10 million | View | Listen | |
| 11/3/2016 | Q3 | ($1.92) | ($1.98) | $4.39 million | $3.73 million | View | N/A | |
| 5/5/2016 | Q1 | ($1.69) | ($2.22) | $2.48 million | $0.31 million | View | N/A | |
| 2/25/2016 | Q4 | ($1.63) | ($1.89) | $3.45 million | $0.23 million | View | Listen | |
| 10/29/2015 | Q315 | ($1.52) | ($1.66) | | $0.09 million | View | Listen | |
| 8/6/2015 | Q215 | ($1.14) | ($1.51) | | | View | Listen | |
| 4/30/2015 | Q115 | ($1.12) | ($1.30) | | | View | Listen | |
| 2/19/2015 | Q414 | ($1.03) | ($1.33) | | | View | Listen | |
| 11/5/2014 | Q314 | ($1.04) | ($1.01) | | | View | N/A | |
| 7/24/2014 | Q214 | ($0.87) | ($1.03) | | | View | N/A | |
| 4/30/2014 | Q114 | ($1.06) | ($1.43) | | | View | N/A | |
| 2/19/2014 | Q413 | ($0.78) | ($0.72) | | | View | N/A | |
| 11/7/2013 | Q313 | ($0.69) | ($0.88) | | | View | N/A | |
| 7/25/2013 | Q2 2013 | ($0.63) | ($0.67) | | | View | N/A | |
| 4/25/2013 | Q1 2013 | ($0.62) | ($0.66) | | | View | N/A | |
| 2/14/2013 | Q4 2012 | ($0.65) | ($15.41) | | | View | N/A | |
| 10/25/2012 | | ($0.55) | ($0.52) | | | View | N/A | |
| 7/26/2012 | | ($0.55) | ($4.11) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for TESARO (NASDAQ:TSRO)2017 EPS Consensus Estimate: ($8.64)
2018 EPS Consensus Estimate: ($4.36)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | ($2.39) | ($1.98) | ($2.20) |
| Q2 2017 | 6 | ($3.10) | ($2.15) | ($2.59) |
| Q3 2017 | 6 | ($2.57) | ($0.52) | ($1.50) |
| Q4 2017 | 6 | ($2.54) | ($1.86) | ($2.35) |
| Q1 2018 | 2 | ($1.56) | ($1.32) | ($1.44) |
| Q2 2018 | 2 | ($1.26) | ($0.93) | ($1.10) |
| Q3 2018 | 2 | ($0.97) | ($0.92) | ($0.95) |
| Q4 2018 | 2 | ($1.18) | ($0.57) | ($0.88) |
(Data provided by Zacks Investment Research)
Dividend History for TESARO (NASDAQ:TSRO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for TESARO (NASDAQ:TSRO)Insider Ownership Percentage: 40.50%
Insider Trades by Quarter for TESARO (NASDAQ:TSRO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/6/2017 | Edward C English | VP | Sell | 8,500 | $138.65 | $1,178,525.00 | |
| 4/3/2017 | Martin H Jr. Huber | SVP | Sell | 829 | $153.02 | $126,853.58 | |
| 3/6/2017 | Edward C English | VP | Sell | 10,000 | $178.06 | $1,780,600.00 | |
| 3/2/2017 | Edward C English | VP | Sell | 229 | $177.61 | $40,672.69 | |
| 3/2/2017 | Grant C. Bogle | SVP | Sell | 1,447 | $177.61 | $257,001.67 | |
| 3/2/2017 | Mary Lynne Hedley | COO | Sell | 3,927 | $177.61 | $697,474.47 | |
| 1/3/2017 | Martin H. Jr. Huber | SVP | Sell | 190 | $136.26 | $25,889.40 | |
| 11/2/2016 | Martin H Jr. Huber | SVP | Sell | 327 | $121.29 | $39,661.83 | |
| 9/22/2016 | Martin H Jr. Huber | SVP | Sell | 408 | $108.12 | $44,112.96 | |
| 9/8/2016 | Edward C English | VP | Sell | 7,000 | $88.54 | $619,780.00 | |
| 8/30/2016 | Jeffrey H Hanke | VP | Sell | 29,166 | $86.04 | $2,509,442.64 | |
| 6/30/2016 | Jeffrey H Hanke | VP | Sell | 12,500 | $74.35 | $929,375.00 | |
| 6/10/2016 | Edward C English | VP | Sell | 7,000 | $40.75 | $285,250.00 | |
| 3/18/2016 | Arnold L Oronsky | Director | Buy | 142,085 | $35.19 | $4,999,971.15 | |
| 3/18/2016 | Enterprise Associates 13 L New | Major Shareholder | Buy | 710,429 | $35.19 | $24,999,996.51 | |
| 3/10/2016 | Edward C English | VP | Sell | 7,000 | $43.71 | $305,970.00 | |
| 12/10/2015 | Edward C. English | VP | Sell | 17,000 | $50.19 | $853,230.00 | |
| 9/8/2015 | James O Armitage | Director | Buy | 500 | $54.63 | $27,315.00 | |
| 12/12/2014 | James O Armitage | Director | Buy | 1,000 | $38.16 | $38,160.00 | |
| 9/29/2014 | Lawrence M Alleva | Director | Buy | 1,100 | $26.17 | $28,787.00 | |
| 7/31/2013 | Lawrence M Alleva | Director | Buy | 1,449 | $34.33 | $49,744.17 | |
| 6/5/2013 | Peter J Barris | Major Shareholder | Sell | 3,583 | $39.00 | $139,737.00 | |
| 4/30/2013 | Lawrence M Alleva | Director | Buy | 1,050 | $28.10 | $29,505.00 | |
| 11/1/2012 | Lawrence M Alleva | Director | Buy | 3,240 | $15.45 | $50,058.00 | |
| 8/30/2012 | Leon O Moulder Jr | CEO | Buy | 10,000 | $11.69 | $116,900.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for TESARO (NASDAQ:TSRO)
Latest Headlines for TESARO (NASDAQ:TSRO)
| Source: |
|
| Date | Headline |
|---|
 | Tesaro: Losing Its Edge? - Barron's
www.barrons.com - August 19 at 8:27 AM |
 | Jefferies Group LLC Reiterates $124.00 Price Target for TESARO, Inc. (TSRO)
www.americanbankingnews.com - August 18 at 11:22 AM |
| TESARO, Inc. (TSRO) Given a $190.00 Price Target by Credit Suisse Group Analysts
www.americanbankingnews.com - August 18 at 8:12 AM |
| TESARO, Inc. (TSRO) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - August 16 at 6:58 PM |
 | See what the IHS Markit Score report has to say about TESARO Inc.
finance.yahoo.com - August 15 at 1:36 AM |
| Research Analysts Offer Predictions for TESARO, Inc.'s Q3 2017 Earnings (NASDAQ:TSRO)
www.americanbankingnews.com - August 11 at 11:40 AM |
| TESARO, Inc. (NASDAQ:TSRO) Expected to Post Q3 2017 Earnings of ($0.66) Per Share
www.americanbankingnews.com - August 11 at 11:40 AM |
| TESARO, Inc. Expected to Post Q3 2017 Earnings of ($0.56) Per Share (NASDAQ:TSRO)
www.americanbankingnews.com - August 11 at 11:40 AM |
| Gabelli Brokers Lower Earnings Estimates for TESARO, Inc. (TSRO)
www.americanbankingnews.com - August 11 at 10:14 AM |
| Q3 2017 EPS Estimates for TESARO, Inc. Cut by Analyst (TSRO)
www.americanbankingnews.com - August 11 at 7:48 AM |
| Q3 2017 EPS Estimates for TESARO, Inc. (TSRO) Boosted by Wedbush
www.americanbankingnews.com - August 11 at 7:48 AM |
| TESARO, Inc. (NASDAQ:TSRO) to Post FY2020 Earnings of $6.84 Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - August 10 at 1:50 PM |
| Oppenheimer Holdings Analysts Lift Earnings Estimates for TESARO, Inc. (NASDAQ:TSRO)
www.americanbankingnews.com - August 10 at 1:32 PM |
| TESARO's (NASDAQ:TSRO) Neutral Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - August 10 at 12:46 PM |
| TESARO, Inc. (NASDAQ:TSRO) Announces Quarterly Earnings Results, Misses Estimates By $0.30 EPS
www.americanbankingnews.com - August 9 at 3:48 PM |
| $16.29 Million in Sales Expected for TESARO, Inc. (NASDAQ:TSRO) This Quarter
www.americanbankingnews.com - August 9 at 7:52 AM |
 | A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision
feeds.benzinga.com - August 8 at 3:23 PM |
| -$2.52 EPS Expected for TESARO, Inc. (NASDAQ:TSRO) This Quarter
www.americanbankingnews.com - August 7 at 8:54 AM |
 | Why Earnings Season Could Be Great for TESARO (TSRO) - Nasdaq
www.nasdaq.com - August 6 at 6:47 AM |
| TESARO, Inc. (NASDAQ:TSRO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 5 at 8:56 PM |
| TESARO, Inc. (NASDAQ:TSRO) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - August 1 at 9:18 PM |
 | TESARO (TSRO), Takeda Enter Pact for Niraparib in Japan - StreetInsider.com
www.streetinsider.com - July 27 at 8:38 AM |
| TESARO, Inc. (NASDAQ:TSRO) to Release Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:54 AM |
| TESARO, Inc. (TSRO) Given a $198.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - July 23 at 3:04 PM |
| Zacks: Brokerages Expect TESARO, Inc. (TSRO) Will Announce Quarterly Sales of $17.22 Million
www.americanbankingnews.com - July 20 at 3:58 PM |
| Brokerages Expect TESARO, Inc. (TSRO) to Post -$2.51 EPS
www.americanbankingnews.com - July 18 at 11:54 AM |
| SunTrust Banks Weighs in on TESARO, Inc.'s FY2018 Earnings (NASDAQ:TSRO)
www.americanbankingnews.com - July 17 at 10:57 AM |
| TESARO, Inc. (NASDAQ:TSRO) Given "Neutral" Rating at Janney Montgomery Scott
www.americanbankingnews.com - July 14 at 7:58 PM |
| Wall Street's M&A Chatter From July 13: Tesaro, Time, Frontier Communications, First Citizens BancShares, Brink's ... - Benzinga
www.benzinga.com - July 14 at 4:22 PM |
 | TESARO Inc (TSRO) Shares Fall as Company Struggles to Find Buyer - Investorplace.com
investorplace.com - July 14 at 4:22 PM |
 | Tesaro Inc. (TSRO) Dropped On Reports That Sale Seems Unlikely
www.rttnews.com - July 14 at 9:27 AM |
| Wall Street's M&A Chatter From July 13: Tesaro, Time, Frontier Communications, First Citizens BancShares, Brink's-Maco Transportadora
feeds.benzinga.com - July 14 at 7:29 AM |
| TESARO Inc (TSRO) Shares Fall as Company Struggles to Find Buyer
investorplace.com - July 13 at 1:28 PM |
 | Tesaro Shows Good Potential With Major Approvals This Year
seekingalpha.com - July 13 at 10:48 AM |
| Tesaro Inc. (TSRO) Is Sinking On Reports That Sale Is Unlikely
www.nasdaq.com - July 13 at 10:48 AM |
 | Sale process for biotech Tesaro seen unlikely to result in deal
www.cnbc.com - July 13 at 10:24 AM |
| Tesaro: Why Gabelli Sees 20%+ Upside - Barron's
www.barrons.com - July 8 at 2:54 PM |
| TESARO, Inc. (TSRO) Now Covered by Gabelli
www.americanbankingnews.com - July 7 at 10:18 AM |
| BidaskClub Downgrades TESARO, Inc. (NASDAQ:TSRO) to Sell
www.americanbankingnews.com - June 30 at 4:04 PM |
| TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference - Nasdaq
www.nasdaq.com - June 29 at 8:42 PM |
| TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference
finance.yahoo.com - June 29 at 3:41 PM |
 | TESARO Announces Lonnie Moulder and Mary Lynne Hedley Named EY Entrepreneurs of the Year® New England - GlobeNewswire (press release)
globenewswire.com - June 29 at 7:33 AM |
| Analysts Anticipate TESARO, Inc. (TSRO) Will Announce Quarterly Sales of $17.22 Million
www.americanbankingnews.com - June 23 at 1:00 PM |
| FY2018 EPS Estimates for TESARO, Inc. Reduced by Leerink Swann (TSRO)
www.americanbankingnews.com - June 22 at 1:04 PM |
| Zacks: Analysts Expect TESARO, Inc. (TSRO) to Announce -$2.55 Earnings Per Share
www.americanbankingnews.com - June 22 at 12:16 AM |
| TESARO, Inc. to Post Q3 2017 Earnings of ($1.64) Per Share, Wedbush Forecasts (TSRO)
www.americanbankingnews.com - June 21 at 8:36 AM |
| TESARO, Inc. (TSRO) Receives "Market Perform" Rating from Raymond James Financial, Inc.
www.americanbankingnews.com - June 20 at 2:56 PM |
| TESARO, Inc. (TSRO) PT Lowered to $143.00 at Leerink Swann
www.americanbankingnews.com - June 20 at 8:10 AM |
| TESARO, Inc. (TSRO) Price Target Cut to $120.00 by Analysts at Janney Montgomery Scott
www.americanbankingnews.com - June 20 at 7:58 AM |
| TESARO, Inc. (TSRO) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - June 19 at 1:32 PM |
TESARO (TSRO) Chart for Sunday, August, 20, 2017
